Clik here to view.
Hansoh Pharma and Atomwise Launch Strategic AI Drug Discovery Collaboration...
SHANGHAI & SAN FRANCISCO Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”), a leading biopharmaceutical company in China, and Atomwise, Inc. (“Atomwise”), the leader in artificial...
View ArticleClik here to view.
翰森制药和Atomwise启动多项治疗领域的人工智能药物发现战略合作
上海和旧金山 (美国商业资讯)–中国领先的生物制药公司翰森制药集团有限公司（Hansoh Pharmaceutical Group Company Limited，“翰森制药”）和药物发现人工智能(AI)领域的领先者Atomwise, Inc. (“Atomwise”)宣布合作设计和发现潜在的候选药物，涉及多项治疗领域最多11个未披露的靶蛋白。 本新闻稿包含多媒体。此处查看新闻稿全文：...
View ArticleClik here to view.
Genome Editing Biotech EdiGene Raises $11 M in Series Pre-B2 Financing and...
BEIJING & CAMBRIDGE, Mass. EdiGene, Inc., which develops genome editing technologies into novel therapeutics for a broad range of diseases and into creative solutions to advance drug discovery,...
View ArticleClik here to view.
Hansoh PharmaとAtomwiseが複数の治療領域を対象としたAI創薬で戦略的協業を開始
上海 & サンフランシスコ （ビジネスワイヤ） — 中国の大手バイオ医薬品企業Hansoh Pharmaceutical Group Company Limited（翰森製薬集団有限公司、ハンソー・ファーマシューティカル）と創薬向け人工知能（AI）分野のリーダー企業Atomwise,...
View ArticleClik here to view.
Solasia Announces Patient Registration Reached Target Number of Cases for...
TOKYO Solasia Pharma K.K. (TSE:4597, Headquarters: Tokyo, President & CEO: Yoshihiro Arai, hereinafter “Solasia”), a specialty pharmaceutical company based in Asia, today announced that patient...
View ArticleClik here to view.
ソレイジア・ファーマ：開発品SP-02 第Ⅱ相臨床試験（最終試験）被験者の目標症例数到達のお知らせ
東京 （ビジネスワイヤ） – 当社は、現在実施中の開発品SP-02（新規抗がん剤、国際一般名：darinaparsin、一般名：ダリナパルシン）の第Ⅱ相臨床試験（以下、「本試験」）について、このたび被験者の登録が目標症例数に到達いたしましたのでお知らせいたします。...
View ArticleClik here to view.
Psomagen and Macrogen Granted U.S. Patent for Blockchain Data-sharing Technology
SEOUL, South Korea The precision medicine and biotechnology company Macrogen (CEO Kap-Seok Yang, www.macrogen.com) announced on September 17 that it had been granted a U.S. patent for its...
View ArticleClik here to view.
Curry Health Network Adopts ClickClean™ Advanced Laparoscopic Technology
GOLD BEACH, Ore. Curry Health Network, an integrated health care delivery system based in Gold Beach, Oregon, today announced that its flagship hospital, Curry General Hospital, has recently adopted...
View ArticleClik here to view.
Riverain Receives $15 Million Growth Capital Investment
MIAMISBURG, Ohio Riverain Technologies, a leading provider of clinical artificial intelligence software used to efficiently detect lung disease at its earliest stages, has received a $15 million...
View ArticleClik here to view.
CDISC Publishes First Standard Using Traditional Chinese Medicine
AUSTIN, Texas CDISC is pleased to announce the first release of a global Therapeutic Area Standard using Traditional Chinese Medicine. Specifically, the standard describes how to use CDISC standards...
View ArticleClik here to view.
CORRECTING and REPLACING CDISC Publishes First Standard Using Traditional...
AUSTIN, Texas Please replace the release with the following corrected version due to multiple revisions in the third paragraph. The corrected release reads: CDISC PUBLISHES FIRST STANDARD USING...
View ArticleClik here to view.
New Data Published in Aesthetic Plastic Surgery Explores the Use of the...
VALENCIA, Calif. & MELBOURNE, Australia AVITA Medical (ASX: AVH) (OTCQX: AVMXY), a regenerative medicine company focused on the development and commercialization of innovative therapies...
View ArticleClik here to view.
SanBio Granted Regenerative Medicine Advanced Therapy Designation from the...
MOUNTAIN VIEW, Calif. The SanBio Group (SanBio Co., Ltd. and SanBio, Inc.)(TOKYO:4592), a scientific leader in regenerative medicine for neurological disorders, today announced that the U.S. Food...
View ArticleClik here to view.
盟科医药宣布新型抗菌药康泰唑胺（Contezolid）针对复杂性皮肤及软组织感染的中国三期临床试验获得积极结果
上海，中国和福斯特城，加州，美国 (美国商业资讯)– 盟科医药今天宣布，其首个抗菌新药康泰唑胺（contezolid，又名MRX-I)，在中国开展的一项治疗复杂性皮肤及软组织感染（cSSTI）的关键性三期临床试验获得积极结果。康泰唑胺在主要终点治愈检验期（TOC，最后一次给药后的7-14天）的临床治愈率，非劣效于利奈唑胺，并显示了更低的药物相关的血液学不良事件。...
View ArticleClik here to view.
MicuRx Reports Positive Top-line Results of a China Phase 3 Clinical Trial...
SHANGHAI & FOSTER CITY, Calif. MicuRx Pharmaceuticals, Inc., today announced positive top-line results from the pivotal Phase 3 clinical trial in China for its lead antibacterial drug candidate...
View ArticleClik here to view.
Solasia宣布，Darinaparsin治疗T细胞淋巴瘤2期枢纽性研究患者登记达到目标病例数
东京 (美国商业资讯)–Solasia Pharma K.K.（TSE:4597，总部：东京，总裁兼首席执行官：Yoshihiro Arai，以下简称“Solasia”）是一家总部位于亚洲的专科制药公司。该公司今天宣布，darinaparsin 2期研究患者登记达到目标病例数。...
View ArticleClik here to view.
NovaBay Pharmaceuticals Receives Approval for Distribution of Avenova in...
EMERYVILLE, Calif. NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova® for the domestic eye care market, announces that it has...
View ArticleClik here to view.
Incyte Announces First Patient Treated in Phase 3 Clinical Trial Program...
WILMINGTON, Del. Incyte (Nasdaq:INCY) today announced that the first patient has been treated in the Phase 3 TRuE-V clinical trial program evaluating the safety and efficacy of ruxolitinib cream as...
View ArticleClik here to view.
ドイツの最高裁判所がアビオメッドの特許の効力を確認
米マサチューセッツ州ダンバース （ビジネスワイヤ） — ドイツの最高裁判所である連邦裁判所は最近、2015年のソラテックによる特許異議申し立てにつき、アビオメッド（NASDAQ: ABMD）に有利な判決を下し、アビオメッドのImpellaと関連した特許の効力を確認しました。 これらの特許は、アビオメッドが2015年にデュッセルドルフ地方裁判所で、ドイツにおけるHeartMate...
View ArticleClik here to view.
Shionogi to Present New Data at IDWeek 2019
OSAKA, Japan & FLORHAM PARK, N.J. Shionogi & Co., Ltd. (hereafter “Shionogi”) today announced that the company will deliver 20 data presentations for Shionogi compounds, including a...
View Article